Effects of Magnesium Oxide on Clinical Equivalence of Rosuvastatin

Effects of Magnesium Oxide on Clinical Equivalence of Rosuvastatin - Effects of Magnesium Oxide on Clinical Equivalence of Rosuvastatin

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025610

Enrollment

100

Registered

2017-02-01

Start date

2017-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperlipidaemia

Interventions

combination therapy group non-combination therapy group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients visiting a hospital for treatment in Fukuoka University Chikushi Hospital department of Cardiology and Endocrinology and Diabetes Mellitus (2)Patients receiving combination therapy with rosuvastatin and a magnesium oxide preparation (3)Written informed consent is obtained from the parents of all patients

Exclusion criteria

Exclusion criteria: (1)Patients who is not be able to sign the consent (2)Patient that it was judged that drug management in being at home had a problem by the principal investigator or subinvestigator (3)Patients receiving drugs both aluminum and magnesium (4)Other patients judged inappropriate by the principal investigator or subinvestigator

Design outcomes

Primary

Measure	Time frame
As the primary end point, we examined the rate of change in the LDL-C level after 12 weeks in patients achieving a compliance of more than 80% based on compliance-checking sheets.	—

Countries

Japan

Contacts

Public ContactOSAMU IMAKYURE

Fukuoka University Chikushi Hospital Department of Hospital Pharmacy

imakyure@fukuoka-u.ac.jp092-921-1011

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026